Seems to me the way to stop these corporate maggots, read "rape-ists" is to put a cap on the price of products imported. If manufacturing costs for a product are X, then a fair market price IS 3-5X to the first tier distributer. A 10 % markup is reasonable for a commodity. That's it though, no more.
A 1 $ epi-pen product costs at worst 1$ to make product and sold to the first reseller, then 5X let's say.. The pen is now 5$. First tier "marketeer" is allowed their 10% so that they sell to the Pharmacy dispensary (now the product is 5.50$ - the Pharmacy/dispensary which should only be allowed a 10 % markup, a final retail to the consumer is $6.05 (quantity pricing obviously can be obtained to reduce the cost even more so).
THAT is fair honest business manufacturing to resales to the public.
TRUMP campaign, if you can read this, you have a WIN - mandate such an above practice.
In the EPI-PEN case, they ESCAPED (remember Mr. Trump when you said US manufacturers were escaping the US to hide elsewhere?) to the Netherlands. THEN they export into the US at outrageous prices. Same practice as listed above is what would be LEGALLY MANDATED - nothing coming in, nothing especially critical medical products should violate the above fair business practices.
That should address the subsidy kickbacks it seems. CAP the cost of imports from manufacturing to retail. ESPECIALLY with critical life saving drugs.
-- update --
to pour a bit more salt on this rape, the company that makes the tech took such from NASA, which publicly developed such a pen, it was created by US FUNDS (see below quote and link)..
To steal such, put their so called 'patent' on such is obscene and a violation of all ethical principles. A license to "rape" is not ethical.
Reference: http://www.anaphylaxis.org.uk/adrena...needle-length/
The "INVERSION ESCAPE PLAN"History of the Adrenaline Auto-Injector
AAIs were first licenced for use in the UK in 1996. AAIs are prescribed for the first line emergency treatment of a severe allergic reaction (anaphylaxis). They are currently available as a prescription only medication in the UK and three brands are available – EpiPen, Jext and Emerade.
Auto-Injectors were developed in the 1960’s for military use following research between the American military and NASA. The original objective was to develop a self-injecting device that would inject atropine, the antidote for nerve agents in biological weapons.
Similar auto-injector systems were also used with other drugs as part of the NASA Manned Space Flight Program. From this original design platform the AAI was developed and was introduced into the medical field approximately 25 years ago in the USA.
The first marketing authorisation in Europe was for EpiPen which was granted in Germany in 1989 and in the UK in March 1996.
Subsequently other brands of AAIs were licensed: Anapen, Jext and most recently Emerade.
Anapen is no longer marketed in the UK but is still available in the other EU countries.
Mylan’s 2014 deal involved its buying a generics manufacturer from Abbott Laboratories and reincorporating in the Netherlands, the subsidiary’s home.
As in all inversions, nothing else changed: Mylan’s operational headquarters remained in Pennsylvania, and its main workforce didn’t relocate.
At one point, Mylan even appealed to U.S. antitrust officials to help it block a takeover bid from an Israeli company. But the inversion deal did allow the firm to cut its U.S. tax bill.
Source: http://www.latimes.com/business/hilt...nap-story.html




Reply With Quote